Hemab Therapeutics

COAGNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$2.319 B

$49.66 -4.79%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

46,705,410

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#30Tarsus PharmaceuticalsTARS$2.79B
#31Biocryst PharmaceuticalsBCRX$2.40B
#32Hemab TherapeuticsCOAG$2.32B
#33VericelVCEL$2.31B
#34Adma BiologicsADMA$2.22B

Where these numbers come from

Share counts and financials for Hemab Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.